MicroRNA-100 Suppresses Human Gastric Cancer Cell Proliferation by Targeting CXCR7
Overview
Affiliations
microRNAs (miRs) are a class of small non-coding RNAs that have been demonstrated to have a crucial role in tumorigenesis of human cancers, including gastric cancer (GC). Previous results have established that miR-100 participated in the development of GC; however, the underlying mechanism remains largely unknown. The preesent study utilized reverse transcription-quantitative polymerase chain reaction to analyze the expression of miR-100 in GC tissues and adjacent normal tissues. The present results indicated that the expression of miR-100 was downregulated in GC tissues when compared to the adjacent normal tissues. Furthermore, low miR-100 expression was observed to be associated with lymph node metastasis, tumor diameter and tumor stage. In addition, Kaplan-Meier analysis revealed that patients with low miR-100 expression tended to have a shorter overall survival. The miR-100 was further identified as an independent prognostic factor for overall survival. Notably, the levels of chemokine (CXC motif) receptor 7 (CXCR7) were inversely correlated with miR-100 in GC cell lines. Furthermore, miR-100 overexpression or CXCR7 depletion decreased GC cell proliferation. Bioinformatics analysis indicated that miR-100 may bind to the 3'-untranslated region of CXCR7 to prevent the initiation of protein translation. Thus, miR-100 may function as a tumor suppressor in GC, partly by regulating the expression of CXCR7, and the regulation of miR-100 expression may be a potential strategy for the treatment of GC patients.
miR‑100: A key tumor suppressor regulatory factor in human malignant tumors (Review).
Zhang L, Zhang J, Zhang X, Liu S, Qi C, Gao S Int J Mol Med. 2025; 55(4).
PMID: 40017111 PMC: 11875724. DOI: 10.3892/ijmm.2025.5508.
Expression and Related Mechanisms of miR-100 and TRIB2 in COPD Patients.
Mai Z, Mi Y, Jiang M, Wan S, Di Q J Healthc Eng. 2022; 2022:6556208.
PMID: 35494527 PMC: 9050250. DOI: 10.1155/2022/6556208.
Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.
Goita A, Guenot D Cancers (Basel). 2022; 14(7).
PMID: 35406582 PMC: 8997717. DOI: 10.3390/cancers14071810.
Azimi M, Totonchi M, Ebrahimi M Cell J. 2022; 24(1):1-6.
PMID: 35182058 PMC: 8876259. DOI: 10.22074/cellj.2022.7173.
Ge Y, Shu J, Shi G, Yan F, Li Y, Ding H J Immunol Res. 2021; 2021:9920786.
PMID: 34337085 PMC: 8313327. DOI: 10.1155/2021/9920786.